Compare URBN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | GRFS |
|---|---|---|
| Founded | 1970 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.2B |
| IPO Year | 1995 | 2008 |
| Metric | URBN | GRFS |
|---|---|---|
| Price | $77.31 | $7.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $86.91 | $10.15 |
| AVG Volume (30 Days) | ★ 1.2M | 376.6K |
| Earning Date | 05-20-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $6,165,376,000.00 | N/A |
| Revenue This Year | $10.67 | $4.49 |
| Revenue Next Year | $7.01 | $6.42 |
| P/E Ratio | $62.07 | ★ $18.67 |
| Revenue Growth | ★ 11.07 | N/A |
| 52 Week Low | $59.54 | $6.96 |
| 52 Week High | $85.43 | $10.23 |
| Indicator | URBN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 48.69 |
| Support Level | $67.23 | $7.66 |
| Resistance Level | $84.15 | $8.36 |
| Average True Range (ATR) | 2.97 | 0.17 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 55.17 | 20.55 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.